MARKET

ADTX

ADTX

Aditxt Inc
NASDAQ
1.760
+0.010
+0.57%
After Hours: 1.730 -0.03 -1.70% 16:57 11/25 EST
OPEN
1.720
PREV CLOSE
1.750
HIGH
1.810
LOW
1.715
VOLUME
51.01K
TURNOVER
0
52 WEEK HIGH
61.50
52 WEEK LOW
1.570
MARKET CAP
7.32M
P/E (TTM)
-0.0218
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/18 21:32
HC Wainwright & Co. Initiates Coverage On Aditxt with Buy Rating, Announces Price Target of $4
Benzinga · 11/14 11:09
--HC Wainwright Starts Aditxt at Buy With $4 Price Target
--HC Wainwright Starts Aditxt at Buy With $4 Price Target
MT Newswires · 11/14 07:48
Aditxt stock rises as manufacturing of immunotherapy begins for planned psoriasis trial
Seekingalpha · 10/21 13:34
BRIEF-Aditxt’S Adimune Program Has Initiated The Manufacturing Process Of Immunotherapeutic Drug Candidate Adi-100
Reuters · 10/21 13:20
Aditxt's Adimune Program Has Initiated the Manufacturing Process Of Immunotherapeutic Drug Candidate, ADI-100 In Preparation For Planned Psoriasis First-In-Human Trials; Shares Spike Higher
Benzinga · 10/21 13:03
Aditxt Announces Development And Publication Of A Mathematical Model For Predicting Longevity And Variations Of Immune Response To Immunization To SARS-CoV-2 Infection
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today
Benzinga · 10/12 13:10
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
RICHMOND, Va., October 12, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces publication of a...
Business Wire · 10/12 13:00
More
About ADTX
Aditxt, Inc., formerly Aditx Therapeutics, Inc., is a biotechnology company. The Company is developing technologies focused on improving the health of the immune system through immune mapping and reprogramming. The Company’s immune mapping technologies are designed to provide a personalized comprehensive profile of the immune system. The Company’s Apoptotic DNA Immunotherapy (ADi) technology has two categories, the AditxtReprogramming therapeutic program, which includes ADi and the AditxtScore diagnostic technology. AditxtScore is designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their immune system. AditxtScore also assists the medical community in anticipating immune responses and reactions to viruses, bacteria, allergens and transplanted organs. ADi is a nucleic acid-based technology that suppresses only those immune cells involved in the rejection of tissue and transplanted organ.

Webull offers kinds of Aditxt Inc stock information, including NASDAQ:ADTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADTX stock methods without spending real money on the virtual paper trading platform.